Iron depletion enhances the effect of sorafenib in hepatocarcinoma

Human hepatocellular carcinoma (HCC) is known to have a poor prognosis. Sorafenib, a molecular targeted drug, is most commonly used for HCC treatment. However, its effect on HCC is limited in clinical use and therefore new strategies regarding sorafenib treatment are required. Iron overload is known...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Cancer Biol Ther
Asıl Yazarlar: Urano, Shinichi, Ohara, Toshiaki, Noma, Kazuhiro, Katsube, Ryoichi, Ninomiya, Takayuki, Tomono, Yasuko, Tazawa, Hiroshi, Kagawa, Shunsuke, Shirakawa, Yasuhiro, Kimura, Fumiaki, Nouso, Kazuhiro, Matsukawa, Akihiro, Yamamoto, Kazuhide, Fujiwara, Toshiyoshi
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Taylor & Francis 2016
Konular:
Research Paper
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC4990399/
https://ncbi.nlm.nih.gov/pubmed/27089255
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/15384047.2016.1177677
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller